M&A - Solomon Grey Capital

Two dark navy marble monoliths at slightly different heights on charcoal marble, separated by an amber shaft of light, editorial 16:9 composition.

M&A

The Megadeal Mood Swing: Why 2026's M&A Boom Is Equity-Led Strategic Urgency, Not Leverage Euphoria Redux

Morgan Stanley is projecting $6.4 trillion of announced M&A in 2026, topping 2021's record. The market is reading this as a leverage cycle redux. Goldman's own survey of 500-plus clients and the financing composition of the largest deals tell a different story: this is a strategic-scale cycle f

A chrome laboratory microscope on dark marble lit by warm amber light — Solomon Grey Capital editorial illustration for the Merck KGaA Bio-Techne $11.3 billion life sciences tools deal.

Healthcare

The Life Sciences Tools Re-Rating: Why Merck KGaA's $11.3 Billion Bid Just Reset a Sub-Sector the Public Market Wrote Off

Merck KGaA's $11.3 billion cash bid for Bio-Techne is not another pharma M&A headline. At 10x sales for a research tools platform, it is a strategic admission that the sub-sector cycle has bottomed and the multiples have over-corrected. The implications run well past one deal.

Research

GSK's $10.6 Billion Nashville: Why the Nuvalent Multiple Just Reset the Patent-Cliff Math for Every Major Drugmaker

John Grey — Healthcare & longevity desk On the morning the markets were busy pricing a US-Iran ceasefire and a Federal Reserve hold, GSK’s new chief executive wrote the largest cheque of his tenure for a Cambridge, Massachusetts biotech that has yet to generate a single dollar of commercial

A closed steel bank vault door in shallow depth of field with a single amber light slice along one edge

Research

Dimon's $20 Billion Patience: Why JPMorgan's M&A Signal Is About the Capital Stack, Not the Deal Pipeline

Markets read Jamie Dimon's Bernstein conference signal as a deal warning. The substance was the opposite — a CEO disciplining his C-suite into holding capital b